The Fly | LEGN

Approved Blockbuster CAR-T Therapy for Multiple Myeloma: Carvykti (cilta-cel) is a leading, highly effective CAR-T therapy for relapsed/refractory multiple myeloma, providing significant market share and revenue.

Strategic Global Commercialization Partnership: Collaboration with Johnson & Johnson provides extensive resources for global market penetration, manufacturing, and regulatory expertise.

Proprietary CAR-T Cell Therapy Platform: Advanced in-house R&D capabilities and a specialized platform for developing highly effective and durable next-generation CAR-T therapies.

Clinical Development Failure: Risk of pipeline candidates failing in trials or Carvykti's label expansion trials not meeting endpoints.

Regulatory Approval Delays or Denial: Challenges in obtaining or maintaining necessary global regulatory approvals for their therapies.

Commercialization and Market Penetration: Difficulties in achieving broad market adoption, securing reimbursement, and competing effectively for Carvykti.

Charts

Strategic Global Commercialization Partnership: Collaboration with Johnson & Johnson provides extensive resources for global market penetration, manufacturing, and regulatory expertise.

Proprietary CAR-T Cell Therapy Platform: Advanced in-house R&D capabilities and a specialized platform for developing highly effective and durable next-generation CAR-T therapies.

Clinical Development Failure: Risk of pipeline candidates failing in trials or Carvykti's label expansion trials not meeting endpoints.

Regulatory Approval Delays or Denial: Challenges in obtaining or maintaining necessary global regulatory approvals for their therapies.

Commercialization and Market Penetration: Difficulties in achieving broad market adoption, securing reimbursement, and competing effectively for Carvykti.

Today

Legend Biotech CEO Ying Huang steps down, Alan Bash named interim CEO